Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q2

9776.TEDINET S100PECX
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥10.0bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥19.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥493m2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥777m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥589m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥821m2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥508m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥717m2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥258m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥458m2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥319m2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥457m2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥16.2bnat 2022-09-30Cons.Assets
Total assets¥16.1bnat 2022-03-31Cons.Assets
Total assets¥15.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥5.7bnat 2022-09-30Cons.Liabilities
Total liabilities¥5.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥10.5bnat 2022-09-30Cons.Net assets
Net assets / equity¥10.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥9.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.7bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥3.0bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥3.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.4bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥674m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥292m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥831m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥430m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥223m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥113m2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥36m2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥77.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥54.092022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥306.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥134.132021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥102.972021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio63.2%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.8%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥46m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥30m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥371m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥356m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥805m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥472m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥333m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥6m
—segment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥9.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥333m
—segment totalsegment profit2022-04-01 → 2022-09-30¥721m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥10.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥334m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥751m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥52m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥52m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥537,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30¥36m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥580m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥411m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥532m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥754m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥13m
—segment totalrevenue2021-04-01 → 2021-09-30¥10.3bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥9.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥754m
—segment totalsegment profit2021-04-01 → 2021-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥755m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥1.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 538
ItemContextValueUnit
Treasury stockPrior1YearInstant-728236000JPY
Treasury stockCurrentQuarterInstant-757451000JPY
Shareholders equityPrior1YearInstant10083073000JPY
Shareholders equityCurrentQuarterInstant10235016000JPY
Valuation difference on available for sale securitiesPrior1YearInstant31227000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant24079000JPY
Valuation and translation adjustmentsPrior1YearInstant31227000JPY
Valuation and translation adjustmentsCurrentQuarterInstant24079000JPY
Non controlling interestsPrior1YearInstant223659000JPY
Non controlling interestsCurrentQuarterInstant284635000JPY
Net assetsPrior1YearInstant10337959000JPY
Net assetsCurrentQuarterInstant10543730000JPY
Liabilities and net assetsPrior1YearInstant16149449000JPY
Liabilities and net assetsCurrentQuarterInstant16234132000JPY
Net salesPrior1YTDDuration9566372000JPY
Net salesCurrentYTDDuration9964353000JPY
Cost of salesPrior1YTDDuration6356915000JPY
Cost of salesCurrentYTDDuration6817070000JPY
Gross profitPrior1YTDDuration3209457000JPY
Gross profitCurrentYTDDuration3147282000JPY
Selling general and administrative expensesPrior1YTDDuration2432273000JPY
Selling general and administrative expensesCurrentYTDDuration2654541000JPY
Operating incomePrior1YTDDuration777183000JPY
Operating incomeCurrentYTDDuration492741000JPY
Interest income noiPrior1YTDDuration139000JPY
Interest income noiCurrentYTDDuration108000JPY
Dividends income noiPrior1YTDDuration3173000JPY
Dividends income noiCurrentYTDDuration2818000JPY
Rent income noiPrior1YTDDuration22576000JPY
Rent income noiCurrentYTDDuration21003000JPY
Subsidy income noi bountyPrior1YTDDuration40785000JPY
Subsidy income noi bountyCurrentYTDDuration90906000JPY
Other noiPrior1YTDDuration8956000JPY
Other noiCurrentYTDDuration14928000JPY
Non operating incomePrior1YTDDuration75630000JPY
Non operating incomeCurrentYTDDuration129765000JPY
Interest expenses noePrior1YTDDuration4595000JPY
Interest expenses noeCurrentYTDDuration4124000JPY
Cost of lease revenue noePrior1YTDDuration24034000JPY
Cost of lease revenue noeCurrentYTDDuration22002000JPY
Other noePrior1YTDDuration3322000JPY
Other noeCurrentYTDDuration6923000JPY
Non operating expensesPrior1YTDDuration31953000JPY
Non operating expensesCurrentYTDDuration33050000JPY
Ordinary incomePrior1YTDDuration820861000JPY
Ordinary incomeCurrentYTDDuration589456000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration133000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration18000JPY
Extraordinary incomePrior1YTDDuration133000JPY
Extraordinary incomeCurrentYTDDuration18000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass